Journal Browser

► Journal Browser

Special Issue Editor

Special Issue Information

Dear Colleagues,

Bones and cartilage form the most important parts of the musculoskeletal system that provides mobility and maintains body posture. Musculoskeletal disorders, namely, those affecting bone and cartilage, limit the mobility and productivity of individuals, leading to early retirement from work and a reduced ability of people to participate in society. Osteoarthritis, rheumatoid arthritis, osteoporosis, and low back pain are the major musculoskeletal disorders and represent a significant socioeconomic burden on individuals and medical services worldwide. A better understanding of the pathophysiology of bone and cartilage in these diseases should provide important clues for the discovery of new therapies. The current Special Issue focuses on molecular and cellular mechanisms underlining bone and cartilage pathology and novel therapeutic approaches targeting the above diseases. We welcome research or review articles focusing on the following topics:

Molecular and cellular mechanisms underlining bone and cartilage pathology in related diseases;
Bone and cartilage metabolism in health and disease;
Therapeutic strategies for prevention of bone and cartilage pathology;
Novel approaches for bone and cartilage regeneration.

Dr. M. Alaa Terkawi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Related Special Issue

Published Papers (2 papers)

Download All Papers

Review

27 pages, 2010 KiB

Open AccessReview

Revisiting Resveratrol as an Osteoprotective Agent: Molecular Evidence from In Vivo and In Vitro Studies

by Haryati Ahmad Hairi, Putri Ayu Jayusman and Ahmad Nazrun Shuid

Biomedicines 2023, 11(5), 1453; https://doi.org/10.3390/biomedicines11051453 - 16 May 2023

Cited by 5 | Viewed by 2020

Abstract

Resveratrol (RSV) (3,5,4′-trihydroxystilbene) is a stilbene found in abundance in berry fruits, peanuts, and some medicinal plants. It has a diverse range of pharmacological activities, underlining the significance of illness prevention and health promotion. The purpose of this review was to delve deeper into RSV’s bone-protective properties as well as its molecular mechanisms. Several in vivo studies have found the bone-protective effects of RSV in postmenopausal, senile, and disuse osteoporosis rat models. RSV has been shown to inhibit NF-κB and RANKL-mediated osteoclastogenesis, oxidative stress, and inflammation while increasing osteogenesis and boosting differentiation of mesenchymal stem cells to osteoblasts. Wnt/β-catenin, MAPKs/JNK/ERK, PI3K/AKT, FoxOs, microRNAs, and BMP2 are among the possible kinases and proteins involved in the underlying mechanisms. RSV has also been shown to be the most potent SIRT1 activator to cause stimulatory effects on osteoblasts and inhibitory effects on osteoclasts. RSV may, thus, represent a novel therapeutic strategy for increasing bone growth and reducing bone loss in the elderly and postmenopausal population. Full article

(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Bone and Cartilage Diseases 2.0)

► Show Figures

Graphical abstract

29 pages, 1131 KiB

Open AccessReview

The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors

by Anna Davydova, Yuliya Kurochkina, Veronika Goncharova, Mariya Vorobyeva and Maksim Korolev

Biomedicines 2023, 11(5), 1328; https://doi.org/10.3390/biomedicines11051328 - 30 Apr 2023

Cited by 2 | Viewed by 2833

Abstract

Spondyloarthritis (SpA) encompasses a group of chronic inflammatory rheumatic diseases with a predilection for the spinal and sacroiliac joints, which include axial spondyloarthritis, psoriatic arthritis, reactive arthritis, arthritis associated with chronic inflammatory bowel disease, and undifferentiated spondyloarthritis. The prevalence of SpA in the population varies from 0.5 to 2%, most commonly affecting young people. Spondyloarthritis pathogenesis is related to the hyperproduction of proinflammatory cytokines (TNFα, IL-17A, IL-23, etc.). IL-17A plays a key role in the pathogenesis of spondyloarthritis (inflammation maintenance, syndesmophites formation and radiographic progression, enthesites and anterior uveitis development, etc.). Targeted anti-IL17 therapies have established themselves as the most efficient therapies in SpA treatment. The present review summarizes literature data on the role of the IL-17 family in the pathogenesis of SpA and analyzes existing therapeutic strategies for IL-17 suppression with monoclonal antibodies and Janus kinase inhibitors. We also consider alternative targeted strategies, such as the use of other small-molecule inhibitors, therapeutic nucleic acids, or affibodies. We discuss advantages and pitfalls of these approaches and the future prospects of each method. Full article

(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Bone and Cartilage Diseases 2.0)

► Show Figures